Institute Of Cancer Research, United Kingdom

This study is testing whether adding a new drug called SX-682 to an existing prostate cancer drug (apalutamide) is safe and can help control advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It will involve about 78 men whose cancer h…

This trial is testing whether adding a new drug called paxalisib to standard chemotherapy (temozolomide) can better control aggressive brain tumors called glioblastoma. It will enroll about 64 adults whose tumors have specific genetic features. The main goals are to see if the co…

This early-stage trial is testing whether a combination of common antibiotics can change the gut bacteria (microbiome) to help a prostate cancer drug work better. It is for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy and ch…

This is an early-stage study to find a safe dose and see if a new drug combination can help the immune system fight advanced cancers. It will test the experimental drug ASTX660 together with the immunotherapy pembrolizumab in up to 61 adults with solid tumors that have stopped re…

This UK trial is testing new oral drug combinations for aggressive brain tumors like glioblastoma. It aims to see if the drugs avutometinib and defactinib, given alone or with a standard chemotherapy, are safe and can help control tumor growth. The study will enroll 182 patients …

This study is testing a new saliva-based DNA test designed to estimate a person's future risk of developing prostate cancer. It aims to recruit 1000 men aged 40-55 from three different ethnic backgrounds to see how well the test works for everyone. Participants identified as high…

This study aims to determine if a PET-CT scan is better than standard MRI and bone scans at finding prostate cancer that has spread in men with specific inherited genetic mutations. Researchers will compare how well each method detects cancer in lymph nodes and distant organs in …

This study is evaluating whether genetic testing can help doctors better understand prostate cancer risk and guide treatment decisions. Researchers will analyze DNA samples from 3,000 men who have prostate cancer or are at high risk for it, looking for genetic variations linked t…

This study aims to understand how prostate cancer progresses in men who have specific inherited gene mutations (like BRCA1/BRCA2) that increase their risk. It will follow over 4,000 men, comparing outcomes for those with and without these mutations. The goal is to gather critical…

This study aims to understand how genetic risk factors affect prostate cancer progression in men who are being monitored rather than immediately treated. Researchers will follow 200 men with low-risk prostate cancer who are on active surveillance, comparing those with higher gene…